Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-9193
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status ; volume:13 ; number:1 ; day:26 ; month:7 ; year:2021 ; pages:1-10 ; date:12.2021
Alzheimer's research & therapy ; 13, Heft 1 (26.7.2021), 1-10, 12.2021
- Urheber
-
Babapour Mofrad, Rosha
Scheltens, Philip
Kim, SangYun
Kang, Sungmin
Youn, Young Chul
An, Seong Soo A.
Tomassen, Jori
Berckel, Bart N. M. van
Visser, Pieter Jelle
Flier, Wiesje M. van der
Teunissen, Charlotte E.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13195-021-00873-w
- URN
-
urn:nbn:de:101:1-2021102408113571579524
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:35 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Babapour Mofrad, Rosha
- Scheltens, Philip
- Kim, SangYun
- Kang, Sungmin
- Youn, Young Chul
- An, Seong Soo A.
- Tomassen, Jori
- Berckel, Bart N. M. van
- Visser, Pieter Jelle
- Flier, Wiesje M. van der
- Teunissen, Charlotte E.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies
Rationally Designed Peptoid Inhibitors of Amyloid‐β Oligomerization
Discordant amyloid-β PET and CSF biomarkers and its clinical consequences
Investigation of oligomerization of amyloid-β and prion protein
Plasma oligomer beta-amyloid is associated with disease severity and cerebral amyloid deposition in Alzheimer’s disease spectrum
Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population
Origins of amyloid-β
Blood amyloid-β oligomerization associated with neurodegeneration of Alzheimer’s disease
PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
Prediction of amyloid PET positivity via machine learning algorithms trained with EDTA-based blood amyloid-β oligomerization data
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic Revisited
Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies
Rationally Designed Peptoid Inhibitors of Amyloid‐β Oligomerization
Discordant amyloid-β PET and CSF biomarkers and its clinical consequences
Investigation of oligomerization of amyloid-β and prion protein
Plasma oligomer beta-amyloid is associated with disease severity and cerebral amyloid deposition in Alzheimer’s disease spectrum
Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population
Origins of amyloid-β
Blood amyloid-β oligomerization associated with neurodegeneration of Alzheimer’s disease
PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
Prediction of amyloid PET positivity via machine learning algorithms trained with EDTA-based blood amyloid-β oligomerization data
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic Revisited
Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies
Rationally Designed Peptoid Inhibitors of Amyloid‐β Oligomerization
Discordant amyloid-β PET and CSF biomarkers and its clinical consequences
Investigation of oligomerization of amyloid-β and prion protein
Plasma oligomer beta-amyloid is associated with disease severity and cerebral amyloid deposition in Alzheimer’s disease spectrum
Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population
Origins of amyloid-β
Blood amyloid-β oligomerization associated with neurodegeneration of Alzheimer’s disease
PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
Prediction of amyloid PET positivity via machine learning algorithms trained with EDTA-based blood amyloid-β oligomerization data
Heterogeneity of Alzheimer’s disease: consequence for drug trials?